iBio, Inc. Common Stock (IBIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $51.55M
Last updated: Nov 17, 2026 at 11:06 AM ET
iBio, Inc. Common Stock (IBIO) Stock Forecast
Analysts expect iBio, Inc. Common Stock (IBIO) to earn -$0.27 per share in the fiscal year ending Jun 30, 2027, on revenue of $20000. Of 9 analysts, 9 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Jun 30, 2027 was revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 1.89, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 11.1% |
| Buy | 8 | 88.9% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Jun 30, 2027
- -$0.27
- EPS consensus, revenue $20000
- Fiscal year ending Jun 30, 2028
- -$0.59
- EPS consensus
- Next report
- Feb 8, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Jun 30, 2027 | -$0.27 | -$0.40 to -$0.22 | 8 | $20000 | N/A | 5 |
| Jun 30, 2028 | -$0.59 | -$1.00 to -$0.26 | 5 | N/A | N/A | 4 |
Quarterly Estimates
Across the 3 quarters below, the EPS consensus is lowest for the quarter ending Jun 30, 2027, at -$0.09, and highest for the quarter ending Dec 31, 2026, at -$0.06.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.06 | -$0.07 to -$0.05 | 3 | $16670 | N/A | 6 |
| Mar 31, 2027 | -$0.07 | -$0.10 to -$0.06 | 7 | N/A | N/A | 6 |
| Jun 30, 2027 | -$0.09 | -$0.13 to -$0.05 | 9 | N/A | N/A | 8 |
Estimate Revisions
Across the 4 periods below, the last 30 days brought 4 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Jun 30, 2027 | 1 | 3 |
| Fiscal year ending Jun 30, 2028 | 3 | 1 |
| Quarter ending Dec 31, 2026 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Jun 30, 2027 has improved from -$0.31.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Jun 30, 2027 | -$0.27 | -$0.38 | -$0.38 | -$0.40 | -$0.31 | N/A |
| Fiscal year ending Jun 30, 2028 | -$0.59 | -$0.61 | -$0.61 | -$0.61 | -$0.56 | N/A |
| Quarter ending Dec 31, 2026 | -$0.06 | -$0.06 | -$0.07 | -$0.08 | -$0.08 | N/A |
| Quarter ending Mar 31, 2027 | -$0.07 | -$0.09 | -$0.09 | -$0.09 | -$0.08 | N/A |
Frequently Asked Questions About IBIO
What is the IBIO stock forecast?
Consensus analyst estimates put iBio, Inc. Common Stock's EPS at -$0.27 for the fiscal year ending Jun 30, 2027, on revenue of $20000. The consensus rating from 9 analysts is Buy.
How do analysts rate IBIO stock?
Of 9 analysts covering iBio, Inc. Common Stock, 1 rates it Strong Buy, 8 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IBIO next year?
For the fiscal year ending Jun 30, 2027, the consensus EPS estimate is -$0.27, with estimates from -$0.40 to -$0.22 from 8 analysts. For the fiscal year ending Jun 30, 2028, the consensus EPS estimate is -$0.59, with estimates from -$1.00 to -$0.26 from 5 analysts.
What revenue do analysts expect from iBio, Inc. Common Stock next year?
For the fiscal year ending Jun 30, 2027, the consensus revenue estimate is $20000.
How many analysts cover IBIO?
9 analysts rate iBio, Inc. Common Stock stock, and 8 analysts estimate its EPS for the fiscal year ending Jun 30, 2027.
IBIO pages: Overview, Earnings, Forecast, Financials, Competitors